logo

For the Inventor, By the Inventor

Burnaby, Canada

Protiva Biotherapeutics, Inc.


USPTO Granted Patents = 46

% Expired Patents = 43.5



Forward Citations = 4,185

Loading Chart...
Loading Chart...

31 inventors (with patents filed for the assignee):

goldMedal Ian MacLachlan (38 out of 50 patents)

silverMedal Lorne Ralph Palmer (19 out of 29 patents)

bronzeMedal James Heyes (16 out of 31 patents)

4.  Lloyd B Jeffs (13 out of 19 patents)

5.  Adam Judge (13 out of 21 patents)

6.  Amy C H Lee (7 out of 13 patents)

7.  Ed Yaworski (7 out of 12 patents)

8.  Edward D Yaworski (5 out of 7 patents)

9.  Kieu Lam (5 out of 9 patents)

10.  Mark Wood (4 out of 19 patents)

11.  Alan Martin (4 out of 10 patents)

12.  Cory Giesbrecht (4 out of 6 patents)

13.  Marjorie Ann Robbins (4 out of 6 patents)

14.  Ellen Grace Ambegia (3 out of 3 patents)

15.  Stephen P Reid (2 out of 6 patents)


Core Competencies:
Nucleic Acid Delivery
Lipid Formulations
Cationic Lipids
Interfering RNA
Therapeutic Agents
Liposomal Apparatus
Gene Silencing
Modified siRNA
Immunostimulatory siRNA
Combination Therapy
Trialkyl Cationic Lipids
Polyethyleneglycol-modified Lipids

46 patents:

1. 12668799 - NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY (2026-06-30),
2. 9926560 - Lipid encapsulating interfering RNA (2018-03-27),
3. 9878042 - Lipid formulations for delivery of therapeutic agents to solid tumors (2018-01-30),
4. 9765333 - Compositions and methods for silencing marburg virus gene expression (2017-09-19),
5. 9518272 - Non-liposomal systems for nucleic acid delivery (2016-12-13),
6. 9504651 - Lipid compositions for nucleic acid delivery (2016-11-29),
7. 9492386 - Liposomal apparatus and manufacturing methods (2016-11-15),
8. 9428751 - Compositions and methods for silencing apolipoprotein C-III expression (2016-08-30),
9. 9404127 - Non-liposomal systems for nucleic acid delivery (2016-08-02),
10. 9364435 - Lipid formulations for nucleic acid delivery (2016-06-14),
11. 9352042 - Trialkyl cationic lipids and methods of use thereof (2016-05-31),
12. 9222086 - Compositions and methods for silencing genes expressed in cancer (2015-12-29),
13. 9181545 - Lipid encapsulating interfering RNA (2015-11-10),
14. 9126966 - Cationic lipids and methods of use thereof (2015-09-08),
15. 9074208 - Modified siRNA molecules and uses thereof (2015-07-07),
Company Overview
Protiva Biotherapeutics, Inc. is a biotechnology company based in Burnaby, Canada, specializing in advanced drug delivery systems. The company focuses on lipid encapsulation technologies to enhance the delivery of therapeutic agents, particularly in the realm of nucleic acid therapeutics. Protiva's expertise includes the development of cationic lipids and liposomal apparatuses, which facilitate gene silencing and the effective delivery of modified siRNA. Their innovative approaches aim to improve treatment outcomes in various diseases through targeted nucleic acid delivery.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

46 Patents

#12 in Burnaby

#303 in Canada

#15,110 in the World

Burnaby, CA
Burnaby, Canada

Protiva Biotherapeutics, Inc.

Forward Citations = 4,185

31 inventors:

goldMedal Ian MacLachlan (38 out of 50 patents)

silverMedal Lorne Ralph Palmer (19 out of 29 patents)

bronzeMedal James Heyes (16 out of 31 patents)

4.  Lloyd B Jeffs (13 out of 19 patents)

5.  Adam Judge (13 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Protiva Biotherapeutics, Inc.. Retrieved from https://idiyas.com/company/protiva-biotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…